ANI Pharmaceuticals’ (ANIP) Buy Rating Reaffirmed at Guggenheim
Guggenheim restated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a research note released on Monday,Benzinga reports. The brokerage currently has a $86.00 price target on the specialty pharmaceutical company’s stock. Several other analysts also recently commented on ANIP. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in […]
Guggenheim restated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Free Report) in a research note released on Monday,Benzinga reports. The brokerage currently has a $86.00 price target on the specialty pharmaceutical company’s stock. Several other analysts also recently commented on ANIP. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in […]
